NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44)
The summary for the NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44): This Funding Opportunity Announcement (FOA) is dedicated to the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to the CREATE Bio Development Track. The FOA supports Investigational New Drug (IND)-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the U.S. Food and Drug Administration (FDA), at a minimum.The program supports early-phase clinical trials, although these are not required.
|Federal Grant Title:||NINDS CREATE Bio Development Track: Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (U44)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PAR-14-289|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Extramural Research Programs in the Neurosciences and Neurological Disorders|
|Current Application Deadline:||May 7, 2017|
|Original Application Deadline:||May 7, 2017|
|Posted Date:||Jul 18, 2014|
|Creation Date:||Jul 18, 2014|
|Archive Date:||Jun 7, 2017|
|Total Program Funding:|
|Maximum Federal Grant Award:||none|
|Minimum Federal Grant Award:||none|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:
1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;
2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;
3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR
(ii) SBIR-only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern; OR
(iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.
4. Has, including its affiliates, not more than 500 employees.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405
- Similar Government Grants
- • NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdocto...
- • Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed)
- • Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (R01 Clinical Trial...
- • The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)
- • Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disord...
- • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44)
- • NINDS Institutional Center Core Grants to Support Neuroscience Research
- • Career Development Award to Promote Diversity in Neuroscience Research
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...